Paid Clinical Trials Billings

Discover 18 paid clinical trials in Billings, Montana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 18

IvonescimabClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Recruiting

PHASE3

Sponsor:

Summit Therapeutics

Location:

Billings MT, Regina, Spokane WA, Lone Tree COshow 39 more

Code:

NCT05899608

Conditions

Non-Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ivonescimab Injection

Pembrolizumab Injection

RAS(ON) Inhibitor CombinationsStudy of RAS(ON) Inhibitor Combinations in Patients with Advanced RAS-mutated NSCLC

Recruiting

PHASE1

PHASE2

Sponsor:

Revolution Medicines, Inc.

Location:

Billings MT, Sacramento CA, San Francisco CA, Stanford CAshow 14 more

Code:

NCT06162221

Conditions

Non-Small Cell Lung Cancer, NSCLC

KRAS, NRAS, HRAS-mutated NSCLC

KRAS G12C-mutated Solid Tumors, Lung Cancer

Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

RAS G12D-mutated NSCLC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RMC-6291

RMC-6236

Pembrolizumab

Cisplatin

Carboplatin

RetatrutideEffect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Billings MT, Idaho Falls ID, Sandy UT, Reno NVshow 26 more

Code:

NCT06297603

Conditions

Type 2 Diabetes

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Retatrutide

Placebo

IanalumabStudy of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Recruiting

PHASE3

Sponsor:

Novartis Pharmaceuticals

Location:

Billings MT, Ogden UT, Aurora CO, Saint Louis Park MNshow 22 more

Code:

NCT05653349

Conditions

Primary Immune Thrombocytopenia (ITP)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Ianalumab

Placebo

Corticosteroids

Buccal Film vs. IV PalonosetronBuccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC

Recruiting

PHASE3

Sponsor:

Xiamen LP Pharmaceutical Co., Ltd

Location:

Billings MT, Chandler AZ, Anaheim CA, Skokie ILshow 8 more

Code:

NCT05199818

Conditions

Chemotherapy-induced Nausea and Vomiting

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Palonosetron HCl Buccal Film 0.5 mg

IV Palonosetron 0.25 mg

Zilovertamab Vedotin & Standard of CareA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Recruiting

PHASE2

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Billings MT, Walnut Creek CA, Whittier CA, Louisville KYshow 11 more

Code:

NCT05139017

Conditions

DLBCL

Diffuse Large B-Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Zilovertamab vedotin

Rituximab

Gemcitabine

Oxaliplatin

Bendamustine

Patritumab Deruxtecan & PembrolizumabStudy of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Recruiting

PHASE2

Sponsor:

Merck Sharp & Dohme LLC

Location:

Billings MT, Tigard OR, Skokie IL, Dallas TXshow 2 more

Code:

NCT06797635

Conditions

Breast Neoplasms

Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Patritumab deruxtecan

Pembrolizumab

Paclitaxel

Carboplatin

Doxorubicin hydrochloride

ImmunotherapyImmunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Billings MT, Anaconda MT, Missoula MT, Coeur d'Alene IDshow 21 more

Code:

NCT06498635

Conditions

Lung Non-Small Cell Carcinoma

Stage II Lung Cancer AJCC v8

Stage IIIA Lung Cancer AJCC v8

Stage IIIB Lung Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Computed Tomography

Durvalumab

Patient Observation

Questionnaire Administration

ABBV-453A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Recruiting

PHASE1

Sponsor:

AbbVie

Location:

Billings MT, Duarte CA, Irvine CA, Houston TXshow 2 more

Code:

NCT06291220

Conditions

Chronic Lymphocytic Leukemia

Small Lymphocytic Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Obinutuzumab

ABBV-453

Combination ImmunotherapiesQUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Recruiting

PHASE2

Sponsor:

ImmunityBio, Inc.

Location:

Billings MT, Sioux Falls SD, Portland OR, Minneapolis MNshow 30 more

Code:

NCT03228667

Conditions

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Urothelial Carcinoma

Head and Neck Squamous Cell Carcinoma

Merkel Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

N-803 + Pembrolizumab

N-803 + Nivolumab

N-803 + Atezolizumab

N-803 + Avelumab

N-803 + Durvalumab